zaurategrast   Click here for help

GtoPdb Ligand ID: 11488

Synonyms: CDP-323 | CDP323
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Zaurategrast (CDP-323) is a small molecule inhibitor of α4-containing integrin complexes that was developed by Celltech [3]. It was intended as a new oral drug treatment for multiple sclerosis [2]. Zaurategrast has the same mechanism of action as the approved MS therapeutic natalizumab. Zaurategrast is an ester prodrug whose active entity is CT7758 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 104.21
Molecular weight 520.11
XLogP 2.64
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(=O)[C@@H](NC1=C(Br)C(=O)C21CCCCC2)Cc1ccc(cc1)Nc1nccc2c1cncc2
Isomeric SMILES OC(=O)[C@@H](NC1=C(Br)C(=O)C21CCCCC2)Cc1ccc(cc1)Nc1nccc2c1cncc2
InChI InChI=1S/C26H25BrN4O3/c27-21-22(26(23(21)32)10-2-1-3-11-26)31-20(25(33)34)14-16-4-6-18(7-5-16)30-24-19-15-28-12-8-17(19)9-13-29-24/h4-9,12-13,15,20,31H,1-3,10-11,14H2,(H,29,30)(H,33,34)/t20-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Clinical development appears to have been terminated due to lack of demonstrable efficacy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00484536 Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323 Phase 2 Interventional UCB Pharma
NCT00726648 CDP323 Biomarker Study Phase 1/Phase 2 Interventional UCB Pharma 4